SCHEDULE: BlackRock Amends Stake in Agios Pharmaceuticals, Reports 7.8% Beneficial Ownership
Beneficial Ownership Report
BlackRock, Inc. has filed an Amendment No. 7 to its Schedule 13G, disclosing a 7.8% beneficial ownership stake in Agios Pharmaceuticals Inc., totaling 4,513,170 common shares.
Summary
- BlackRock, Inc. filed an Amendment No. 7 to its Schedule 13G regarding its beneficial ownership in AGIOS PHARMACEUTICALS INC.
- As of June 30, 2025, BlackRock, Inc. beneficially owns an aggregate of 4,513,170 shares of Common Stock, representing 7.8% of the class.
- BlackRock holds sole voting power over 4,375,383 shares and sole dispositive power over 4,513,170 shares.
- No shared voting or dispositive power is reported.
- The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
- Several BlackRock subsidiaries are identified as having beneficial ownership, with BlackRock Investment Management, LLC specifically noted as owning 5% or greater of the outstanding shares.
Sentiment
Score: 6
Explanation: The filing is a routine disclosure of a passive ownership stake by a large institutional investor. While not directly indicative of the issuer's performance, a significant stake from a firm like BlackRock can be viewed as a neutral to slightly positive signal of institutional confidence, without implying any active management or strategic involvement.
Positives
- A significant stake by a major institutional investor like BlackRock, Inc. (7.8%) may indicate long-term confidence in Agios Pharmaceuticals Inc.
Future Outlook
NA
Industry Context
Schedule 13G filings are standard disclosures by institutional investors holding more than 5% of a company's stock, indicating a passive investment intent. BlackRock, as one of the world's largest asset managers, frequently appears in such filings across numerous public companies, reflecting its broad investment mandates. This filing provides transparency regarding its significant, non-controlling stake in Agios Pharmaceuticals Inc.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder, potentially reinforcing confidence due to BlackRock's passive investment.
- Management: Awareness of a large, passive institutional shareholder, though without direct influence on control.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney revoked by BlackRock, Inc. |
| 2025-01-21 | Effective date of the new Power of Attorney granted by BlackRock, Inc. |
| 2025-06-30 | Date of event requiring the filing of this Schedule 13G Amendment No. 7. |
| 2025-07-17 | Signature date of the Schedule 13G Amendment No. 7 by BlackRock, Inc. |
Keywords
Agios Pharmaceuticals, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, AGIO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.